Stockreport

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]

Structure Therapeutics Inc.  (GPCR) 
PDF Aleniglipron's oral, non-peptide, once-daily profile with injectable-level efficacy and improved tolerability positions GPCR as a potential best-in-class oral GLP-1 the [Read more]